Literature DB >> 27336397

Long-term Metabolic Outcomes of Functioning Pancreas Transplants in Type 2 Diabetic Recipients.

Sung Shin1, Chang Hee Jung, Ji Yoon Choi, Hyun Wook Kwon, Joo Hee Jung, Young Hoon Kim, Duck Jong Han.   

Abstract

BACKGROUND: Limited data are available regarding the long-term metabolic outcomes of functioning pancreas transplants in patients with type 2 diabetes mellitus (T2DM).
METHODS: To compare the long-term effects of pancreas transplantation in terms of insulin resistance and β cell function, comparison of metabolic variables was performed between type 1 diabetes mellitus (T1DM) and T2DM patients from 1-month posttransplant to 5 years using generalized, linear-mixed models for repeated measures.
RESULTS: Among 217 consecutive patients who underwent pancreas transplantation at our center between August 2004 and January 2015, 193 patients (151 T1DM and 42 T2DM) were included in this study. Throughout the follow-up period, postoperative hemoglobin A1c did not differ significantly between T1DM and T2DM patients, and the levels were constantly below 6% (42 mmol/mol) until 5 years posttransplant, whereas C-peptide was significantly higher in T2DM (P = 0.014). There was no difference in fasting insulin, homeostasis model assessment (HOMA) of insulin resistance, HOMA β cell, or the insulinogenic index between the groups. Furthermore, fasting insulin and HOMA-insulin resistance steadily decreased in both groups during the follow-up period.
CONCLUSIONS: There was no significant difference in the insulin resistance or β-cell function after pancreas transplantation between T1DM and T2DM patients. We demonstrated that pancreas transplantation is capable of sustaining favorable endocrine functions for more than 5 years in T2DM recipients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27336397     DOI: 10.1097/TP.0000000000001269

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  A comparative study of pancreas transplantation between type 1 and 2 diabetes mellitus.

Authors:  Bor-Shiuan Shyr; Bor-Uei Shyr; Shih-Chin Chen; Che-Chuan Loong; Yi-Ming Shyr; Shin-E Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2021-08       Impact factor: 7.293

2.  Single center results of simultaneous pancreas-kidney transplantation in patients with type 2 diabetes.

Authors:  Phuoc H Pham; Lily N Stalter; Eric J Martinez; Jesse F Wang; Bridget M Welch; Glen Leverson; Nicholas Marka; Talal Al-Qaoud; Didier Mandelbrot; Sandesh Parajuli; Hans W Sollinger; Dixon Kaufman; Robert R Redfield; Jon S Odorico
Journal:  Am J Transplant       Date:  2021-01-15       Impact factor: 9.369

3.  Beneficial effects of posttransplant dipeptidyl peptidase-4 inhibitor administration after pancreas transplantation to improve β cell function.

Authors:  Hye-Won Jang; Chang Hee Jung; Youngmin Ko; Seong Jun Lim; Hye Eun Kwon; Joo Hee Jung; Hyunwook Kwon; Young Hoon Kim; Sung Shin
Journal:  Ann Surg Treat Res       Date:  2021-08-31       Impact factor: 1.859

4.  Assessing Pancreas Transplant Candidate Cardiac Disease: Preoperative Protocol Development at a Rapidly Growing Transplant Program.

Authors:  David St Michel; Tracy Donnelly; Towanda Jackson; Bradley Taylor; Rolf N Barth; Jonathan S Bromberg; Joseph R Scalea
Journal:  Methods Protoc       Date:  2019-10-17

5.  Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.

Authors:  Paul A Allegretti; Timothy M Horton; Yassan Abdolazimi; Hannah P Moeller; Benjamin Yeh; Matthew Caffet; Guillermina Michel; Mark Smith; Justin P Annes
Journal:  Bioorg Med Chem       Date:  2019-11-11       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.